Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AMAR NASDAQ:ANCN NASDAQ:IMRN OTCMKTS:KAYS NASDAQ:MYOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.00$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsANCNAnchiano Therapeutics$1.16-0.3%$21.77$0.51▼$10.55$8.58M0.933.15 million shs68,069 shsIMRNIMMURON$1.72-14.2%$5.04$1.50▼$2.87$10.32M0.8214,894 shs12,391 shsKAYSKaya$0.03-13.7%$0.04$0.02▼$0.05$810K0.2710,351 shs4,000 shsMYOSMYOS RENS Technology$3.35$0.74▼$3.85$16.70M1.081.68 million shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%ANCNAnchiano Therapeutics-0.85%0.00%-10.77%+23.40%+13.73%IMRNIMMURON-3.05%-5.19%-3.00%-3.38%-17.50%KAYSKaya-13.70%-7.08%-10.00%-19.23%-27.07%MYOSMYOS RENS Technology0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMARAmarillo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMRNIMMURON1.3557 of 5 stars3.53.00.00.00.60.00.0KAYSKayaN/AN/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo Biosciences 0.00N/AN/AN/AANCNAnchiano Therapeutics 0.00N/AN/AN/AIMRNIMMURON 3.00Buy$5.00191.38% UpsideKAYSKaya 0.00N/AN/AN/AMYOSMYOS RENS Technology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00ANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/AIMRNIMMURON$3.21M3.13N/AN/A$1.46 per share1.18KAYSKaya$10K69.84N/AN/A($0.77) per share-0.04MYOSMYOS RENS Technology$1.03M0.00N/AN/A$0.13 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/AANCNAnchiano Therapeutics-$27.12M-$3.467.73N/AN/AN/A36.08%27.40%N/AIMRNIMMURON-$4.55MN/A0.00N/AN/AN/AN/AN/AN/AKAYSKaya-$2.08M-$0.08N/A∞N/AN/AN/A-1,044.25%8/13/2025 (Estimated)MYOSMYOS RENS Technology-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/ALatest ANCN, AMAR, IMRN, KAYS, and MYOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025KAYSKayaN/A-$0.04N/A-$0.04N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AIMRNIMMURONN/AN/AN/AN/AN/AKAYSKayaN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07ANCNAnchiano TherapeuticsN/A3.253.25IMRNIMMURONN/A6.805.92KAYSKayaN/A0.010.01MYOSMYOS RENS Technology0.113.781.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/AANCNAnchiano Therapeutics9.05%IMRNIMMURON0.12%KAYSKayaN/AMYOSMYOS RENS Technology4.97%Insider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%ANCNAnchiano Therapeutics6.88%IMRNIMMURON7.01%KAYSKaya23.52%MYOSMYOS RENS Technology45.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableIMRNIMMURONN/A5.85 million5.44 millionNot OptionableKAYSKaya422.17 million16.96 millionNot OptionableMYOSMYOS RENS Technology1512.19 millionN/ANot OptionableANCN, AMAR, IMRN, KAYS, and MYOS HeadlinesRecent News About These CompaniesRen Systems Raises $3.5M, Partners With ZoomInfo to Bring AI-powered Relationship Intelligence to Dealmakers at 35,000 BusinessesSeptember 11, 2024 | venturebeat.comVNew Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12July 25, 2024 | tmcnet.comRen Zhengfei says US government 'underestimates' HuaweiDecember 23, 2023 | bbc.comBPioneer announces The Ren as Business Partner of the YearNovember 20, 2023 | richlandsource.comRShenqiang RenOctober 4, 2023 | buffalo.eduBAnthony M. Newman to Lead REN-ISAC Cybersecurity CenterAugust 27, 2023 | campustechnology.comCCarbon-based quantum technologyAugust 19, 2023 | sciencedaily.comSBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]May 11, 2023 | marketwatch.comLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsMay 8, 2023 | marketwatch.comBio-active Peptides Market Size Dynamics 2023-2029April 13, 2023 | marketwatch.comRenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platformApril 6, 2023 | cointelegraph.comGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027March 21, 2023 | marketwatch.comBio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027March 13, 2023 | marketwatch.comCan Huawei thrive despite American sanctions?October 29, 2022 | economist.comEBio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028September 28, 2022 | marketwatch.comBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries DataAugust 4, 2022 | marketwatch.comRenaissance Festival tickets go on sale Friday, Aug. 5August 1, 2022 | independenttribune.comIRensair raises $7m to establish clean air as a human rightMay 10, 2022 | wfmz.comWBioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026January 12, 2022 | wicz.comWBioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.November 1, 2021 | chipdesignmag.comCMedia Sentiment Over TimeANCN, AMAR, IMRN, KAYS, and MYOS Company DescriptionsAmarillo Biosciences OTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.Anchiano Therapeutics NASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.IMMURON NASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Kaya OTCMKTS:KAYS$0.03 -0.01 (-13.70%) As of 07/11/2025 03:29 PM EasternKaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.MYOS RENS Technology NASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
